Stocks:
5,168
ETFs:
2,288
Exchanges:
11
Market Cap:
$65.69T
24h Vol:
$10.68B
Dominance:
MSFT:4.75%
Stocklytics Platform
Asset logo  HGEN
Humanigen
HGEN
62 / 100
High Growth
$57.40arrow_drop_up0.70%$0.40

Performance History

Stocklytics logo
Key Stats
Open$55.76
Prev. Close$57.00
EPS-0.51
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap74195168.00
PE Ratio-
LOWHIGH
Day Range55.20
58.80
52 Week Range40.33
104.49
Ratios
P/B Ratio9.20
Revenue$2.51M
Operating M. %-1,916.29%
Earnings$0.00
Earnings Growth %70.11%
EBITDA Margin %-357.19%
ROE %-2,165.43%
EPS-0.51

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Financial Forecast

AI Price Prediction

line chart placeholder

Analyst Ratings

info
Analyst ratings for this stock instrument are based on analysts' assumptions and should not be solely relied upon for financial decisions.

Correlated Companies

PRICE$771.12
24H (%)arrow_drop_down2.02%
24H ($)-$15.90
MARKET CAP$722.30B
PRICE$521.27
24H (%)arrow_drop_up0.71%
24H ($)$3.72
MARKET CAP$471.98B
PRICE$154.28
24H (%)arrow_drop_up1.05%
24H ($)$1.61
MARKET CAP$360.78B
PRICE$130.88
24H (%)arrow_drop_down0.64%
24H ($)-$0.84
MARKET CAP$329.41B

About Humanigen (HGEN)

Humanigen, Inc., a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response. The company is developing lenzilumab, an antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF), to treat cytokine storm associated with COVID-19 for which it has completed a Phase 3 study and is the focus of a Phase 2/3 study sponsored by the NIH. It is also developing lenzilumab, which is associated with CD19-targeted CAR-T cell therapies, as well as exploring the effectiveness of lenzilumab in other inflammatory conditions, such as acute Graft versus Host Disease in patients undergoing allogeneic hematopoietic stem cell transplantation and in eosinophilic asthma, and rheumatoid arthritis. In addition, the company focuses on studying lenzilumab for patients with chronic myelomonocytic leukemia exhibiting RAS pathway mutations. Its pipeline also includes two other Humaneered monoclonal antibodies, ifabotuzumab, which binds to EphA3, and HGEN005, which targets EMR1, as well as treats a range of eosinophilic diseases, including eosinophilic leukemia as an optimized naked antibody and as the backbone for a novel CAR-T construct. Humanigen, Inc. was incorporated in 2000 and is headquartered in Short Hills, New Jersey.

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Cameron Durrant M.D., MBA
Headquarters
Short Hills
Employees
6
Exchange
OTC
add Humanigen to watchlist

Keep an eye on Humanigen

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help
What is Humanigen's (HGEN) price per share?

The current price per share for Humanigen (HGEN) is $57. The stock has seen a price change of $0 recently, indicating a 0% change. This reflects the stock's recent market performance and investor sentiment.

help
What is the 52-week high and low for Humanigen (HGEN)?

For Humanigen (HGEN), the 52-week high is $104.49, which is 83.32% from the current price. The 52-week low is $40.34, the current price is 41.31% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help
Is Humanigen (HGEN) a growth stock?

Humanigen (HGEN) has shown an average price growth of 0.41% over the past three years. It has received a score of 100 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Humanigen as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help
What is Humanigen (HGEN) stock price performance year to date (YTD)?

As of the latest data, Humanigen (HGEN) has a year-to-date price change of .

help
Is Humanigen (HGEN) a profitable company?

Humanigen (HGEN) has a net income of -$70.73M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -1.92K% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $2.51M, although specific revenue growth data is currently not available. The gross profit is $2.51M. Operating income is noted at -$68.3M. Furthermore, the EBITDA is $0.

help
What is the market capitalization of Humanigen (HGEN)?

Humanigen (HGEN) has a market capitalization of $74.2M. The average daily trading volume is 276.58K, indicating the stock's liquidity and investor engagement.

News

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level